Lexaria Bioscience (LEXX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lexaria Bioscience’s recent animal study reveals promising 12-week results for its DehydraTECH-liraglutide and select CBD formulations in enhancing weight loss, outperforming traditional GLP-1 drugs like semaglutide. The study, which focused on drug delivery innovations, showed accelerated weight loss in the final weeks, highlighting the potential of Lexaria’s technology in diabetes treatment.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.